Akeso's immuno-oncology segment is dedicated to the research, development, and commercialization of innovative antibody drugs targeting various cancers. This segment focuses on developing first-in-class and best-in-class therapies, including bispecific antibodies like cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF). The company conducts extensive clinical trials to evaluate the efficacy and safety of these drugs across a range of solid tumors, such as lung, gastric, and cervical cancers. Akeso's strategic partnerships and collaborations further enhance its capabilities in this area, allowing for the exploration of novel combinations and indications. The ultimate goal is to improve patient outcomes and transform the treatment landscape for cancer patients worldwide.